{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"125"},{"groupId":"OG001","value":"54"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"61"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"24"}]}],"title":"Any TEAE, 25 months (DCO: Nov 8, 2019)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"125"},{"groupId":"OG001","value":"54"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"61"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"24"}]}],"title":"Any TEAE, 36 months (DCO: Dec 11, 2020)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"122"},{"groupId":"OG001","value":"51"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"56"},{"groupId":"OG004","value":"19"},{"groupId":"OG005","value":"24"}]}],"title":"Drug-related TEAEs, 25 months (DCO: Nov 8, 2019)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"122"},{"groupId":"OG001","value":"51"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"56"},{"groupId":"OG004","value":"19"},{"groupId":"OG005","value":"24"}]}],"title":"Drug-related TEAEs, 36 months (DCO: Dec 11, 2020)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"15"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"11"}]}],"title":"Serious TEAEs, 25 months (DCO: Nov 8, 2019)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"16"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"11"}]}],"title":"Serious TEAEs, 36 months (DCO: Dec 11, 2020)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"6"}]}],"title":"Drug-related serious TEAEs, 25 months (DCO: Nov 8, 2019)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"6"}]}],"title":"Drug-related serious TEAEs, 36 months (DCO: Dec 11, 2020)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"1"}]}],"title":"TEAEs associated with drug withdrawn, 25 months (DCO: Nov 8, 2019)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"1"}]}],"title":"TEAEs associated with drug withdrawn, 36 months (DCO: Dec 11, 2020)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"}]}],"title":"Drug-related TEAEs associated with drug withdrawn, 25 months (DCO: Nov 8, 2019)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"}]}],"title":"Drug-related TEAEs associated with drug withdrawn, 36 months (DCO: Dec 11, 2020)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"21"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"8"}]}],"title":"TEAEs associated with dose reduced, 25 months (DCO: Nov 8, 2019)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"21"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"8"}]}],"title":"TEAEs associated with dose reduced, 36 months (DCO: Dec 11, 2020)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"21"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"7"}]}],"title":"Drug-related TEAEs associated with dose reduced, 25 months (DCO: Nov 8, 2019)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"21"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"7"}]}],"title":"Drug-related TEAEs associated with dose reduced, 36 months (DCO: Dec 11, 2020)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"10"}]}],"title":"TEAEs associated with drug interrupted, 25 months (DCO: Nov 8, 2019)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"10"}]}],"title":"TEAEs associated with drug interrupted, 36 months (DCO: Dec 11, 2020)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"19"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"10"}]}],"title":"Drug-related TEAE associated with drug interrupted, 25 months (DCO: Nov 8, 2019)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"19"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"10"}]}],"title":"Drug-related TEAE associated with drug interrupted, 36 months (DCO: Dec 11, 2020)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"0"}]}],"title":"TEAEs associated with death, 25 months (DCO: Nov 8, 2019)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"0"}]}],"title":"TEAEs associated with death, 36 months (DCO: Dec 11, 2020)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"125"},{"groupId":"OG001","value":"55"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"62"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"24"}],"units":"Participants"}],"description":"A treatment-emergent adverse event (TEAE) is defined as an adverse event that occurs, having been absent before the first dose of study drug, or has worsened in severity or seriousness after the initiating the study drug until 47 days after last dose of the study drug. Serious adverse events (SAEs) with an onset or worsening 48 days or more after the last dose of study drug, if considered related to the study treatment, are also TEAEs.","groups":[{"description":"Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive DS-8201a once every 3 weeks.","id":"OG000","title":"DS-8201a"},{"description":"Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive irinotecan monotherapy as prescribed by the physician before enrollment.","id":"OG001","title":"Physician's Choice Irinotecan"},{"description":"Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive paclitaxel monotherapy as prescribed by the physician before enrollment.","id":"OG002","title":"Physician's Choice Paclitaxel"},{"description":"Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive either irinotecan or paclitaxel monotherapy as prescribed by the physician before enrollment.","id":"OG003","title":"Physician's Choice Overall"},{"description":"Non-randomized participants with HER2 IHC 2+/ISH- advanced gastric or gastroesophageal junction adenocarcinoma who received DS-8201a once every three weeks.","id":"OG004","title":"Exploratory: Naïve HER2 IHC 2+/ISH-, DS-8201a"},{"description":"Non-randomized participants with HER2 IHC 1+ advanced gastric or gastroesophageal junction adenocarcinoma who received DS-8201a once every 3 weeks.","id":"OG005","title":"Exploratory: Naïve HER2 IHC 1+, DS-8201a"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Adverse events were assessed in the Safety Analysis Set.","reportingStatus":"POSTED","timeFrame":"Baseline up to 47 days after last dose, up to 36 months postdose","title":"Overall Summary of Treatment-emergent Adverse Events (TEAEs) Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. (Safety Analysis Set)","type":"SECONDARY","unitOfMeasure":"Participants"}